INT124259

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.11
First Reported 2004
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 4
Total Number 7
Disease Relevance 1.74
Pain Relevance 0.31

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (Jun) peptidase activity (Plat) extracellular space (Plat)
extracellular region (Plat) nucleus (Jun) DNA binding (Jun)
Plat (Mus musculus)
Jun (Mus musculus)
Pain Link Frequency Relevance Heat
cytokine 10 78.08 Quite High
Inflammation 38 77.68 Quite High
Pain 3 74.56 Quite High
COX2 3 25.00 Low Low
metalloproteinase 12 5.00 Very Low Very Low Very Low
cINOD 4 5.00 Very Low Very Low Very Low
cerebral cortex 2 5.00 Very Low Very Low Very Low
Analgesic 2 5.00 Very Low Very Low Very Low
Paracetamol 2 5.00 Very Low Very Low Very Low
Potency 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Necrosis 2 90.60 High High
Cancer 37 90.24 High High
Stress 18 79.84 Quite High
INFLAMMATION 43 77.68 Quite High
Pain 3 74.56 Quite High
Apoptosis 44 74.08 Quite High
Skin Cancer 10 70.88 Quite High
Disease 12 65.00 Quite High
Breast Cancer 12 48.24 Quite Low
Coronary Artery Disease 2 43.16 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
While TPA-induced activation of nuclear factor-(kappa)B remained unaffected by both extracts, they inhibited TPA-induced activation of activator protein-1 (AP-1) and attenuated the expression of its key component c-Fos.
Negative_regulation (inhibited) of TPA Positive_regulation (activation) of activator protein-1
1) Confidence 0.11 Published 2005 Journal Cancer Lett. Section Abstract Doc Link 15639337 Disease Relevance 0.35 Pain Relevance 0.17
Several trans-stilbenes were identified that inhibit TPA-induced activation of AP-1, with IC50 values as low as 0.5 ?
Negative_regulation (inhibit) of TPA Positive_regulation (activation) of AP-1
2) Confidence 0.07 Published 2008 Journal BMC Pharmacol Section Abstract Doc Link PMC2632638 Disease Relevance 0.31 Pain Relevance 0.08
In this series, many compounds were strong inhibitors of the TPA-induced activation of AP-1, such as 46, 47, 48, 49and 51(Table 1).
Negative_regulation (inhibitors) of TPA Positive_regulation (activation) of AP-1
3) Confidence 0.07 Published 2008 Journal BMC Pharmacol Section Body Doc Link PMC2632638 Disease Relevance 0 Pain Relevance 0
We report here that substituted trans-stilbenes devoid of anti-oxidant activity can function as inhibitors of the TPA-induced activation of AP-1.
Negative_regulation (inhibitors) of TPA Positive_regulation (activation) of AP-1
4) Confidence 0.07 Published 2008 Journal BMC Pharmacol Section Body Doc Link PMC2632638 Disease Relevance 0.12 Pain Relevance 0.03
Substituted trans-stilbenes represent a class of compounds that can inhibit or enhance the TPA-induced activation of AP-1.
Negative_regulation (inhibit) of TPA Positive_regulation (activation) of AP-1
5) Confidence 0.07 Published 2008 Journal BMC Pharmacol Section Body Doc Link PMC2632638 Disease Relevance 0.40 Pain Relevance 0.04
suggest that the inhibition of TPA-induced AP-1 activity and cell
Negative_regulation (inhibition) of TPA Positive_regulation (induced) of AP-1
6) Confidence 0.02 Published 2004 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC1082887 Disease Relevance 0.17 Pain Relevance 0
have been shown to inhibit TPA-induced AP-1 transcriptional
Negative_regulation (inhibit) of TPA Positive_regulation (induced) of AP-1
7) Confidence 0.02 Published 2004 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC1082887 Disease Relevance 0.39 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox